exciting day today!, page-37

PRR is being hit because

a) Our much loved CEO has completely failed to upate the market in respect of the NASDAQ listing; and

b) DNDN substantially revised down their estimated sales forcasts in the US overnight, which has seen more than a 60% plunge in their share price during EXTENDED TRADING, that is, after the market has closed.

The extended trading plunge of DNDN could be a big fake-out, but the revised estimates are due to the slow up-take of Provenge by physicians, due to their not being properly schooled in the insurance reimbursement now afforded to the drug - so it has nothing to do with the effectiveness of Provenge, it only has everything to do with how soon DNDN will be pulling revenues in, as they had earlier estimated. See more here:

http://www.bloomberg.com/news/2011-08-03/dendreon-scraps-sales-forecast-on-slow-prostate-drug-sales-shares-plunge.html?cmpid=yhoo

So the US market is giving DNDN a hiding for getting their sums wrong.

The US market will buy back into DNDN once their estimates start hitting targets. But right now represents a buying opportunity for DNDN.

PRR is being directly affected by this DNDN news, and I believe we will see a strong surge back into PRR once this absolute flogging of the PRR tree is done with.

Oh, and thanks Martin Rogers for that timely update about what is going on with our US listing - great way to instill confidence and provide support for the SP.



good luck